Atavistik Bio is a new, privately-held biopharmaceutical company focused on the discovery and development of novel therapies for metabolic diseases and cancer. Our high-throughput platform for the unbiased identification of metabolite-protein interactions will enable the discovery of first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems to apply to genetically validated targets.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $100M
Founded date: 2021
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.12.2023 | - | $40M | - |
| 24.08.2021 | Series A | $60M | - |
Mentions in press and media 9
| Date | Title | Description | Source |
| 22.12.2023 | Atavistik Bio Raises Additional $40M in Funding | Atavistik Bio, a Cambridge, MA-based biotechnology company discovering precision allosteric therapeu... | finsmes.co... |
| 19.12.2023 | Atavistik Bio Lands Additional $40M | CAMBRIDGE, MA, Atavistik Bio today announced that it has raised an additional $40 million in fundi... | vcnewsdail... |
| 19.12.2023 | Atavistik Bio Raises Additional $40 Million to Advance Preci... | - | globenewsw... |
| 10.01.2023 | Atavistik Bio Announces Collaboration with Plex Research to ... | Proprietary AMPS platform enables the systematic and rapid interrogation of protein-metabolite inter... | aithority.... |
| 31.08.2021 | Digital health news, funding roundup in the prior week; Augu... | Headspace's resilience brand and Ginger's clinical heft create mental health powerhouse Bambi Franc... | vator.tv/n... |
| 25.08.2021 | Daily funding roundup - August 24th, 2021 | Bridge to Life raised $56M; Covera Health landed $25M; Equum Medical secured $20M Ramp: Ramp is a N... | vator.tv/n... |
| 24.08.2021 | Atavistik Bio : Announces $60 Million Series A Financing to ... | Atavistik Bio (“Atavistik”, “Company”), a pre-clinical biotechnology company pioneering the identifi... | marketscre... |
| 24.08.2021 | Atavistik Bio Raises $60M in Series A Financing | John A. Josey, PhD, Acting CEO of Atavistik Bio, and Marion Dorsch, PhD, President and CSO. (Photo: ... | finsmes.co... |
| - | Atavistik Bio | “Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug ... | fastfounde... |